[Intensive atorvastatin therapy in patients with acute myocardial infarction]

Lan-feng Wang1, Zhu-qin Li, Qing Tang

  • 1Department of Cardiology, First Affiliated Hospital of Harbin Medical University, Harbin 150001, China. bluetime_20@163.com

Insights

High-dose atorvastatin (40 mg daily) effectively reduces LDL cholesterol and C-reactive protein in acute myocardial infarction patients, with manageable liver enzyme elevations. This intensive therapy is safe and beneficial for AMI recovery.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acute myocardial infarction (AMI) is a leading cause of cardiovascular mortality.
  • Statins, particularly atorvastatin, are crucial in managing cardiovascular risk post-AMI.
  • Optimizing statin dosage is essential for maximizing therapeutic benefits.

Purpose of the Study:

  • To evaluate the safety and efficacy of high-dose (40 mg daily) atorvastatin in patients following an acute myocardial infarction.
  • To assess the impact of intensive atorvastatin therapy on lipid profiles and inflammatory markers.

Main Methods:

  • A cohort of 1102 patients with AMI received atorvastatin 40 mg daily within 24 hours of admission.
  • Dosage was adjusted to 20 mg daily for patients with low LDL-C or elevated liver enzymes at discharge.
  • Lipid profiles, high-sensitivity C-reactive protein (hs-CRP), and liver enzymes were monitored at admission, discharge, and 3 months post-discharge.

Main Results:

  • Atorvastatin significantly reduced LDL-C, HDL-C (initially), TC, and apoB levels throughout the study period (P < 0.05).
  • High-sensitivity C-reactive protein (hs-CRP) levels demonstrated a significant decrease from admission to 3 months post-discharge (P < 0.05).
  • Transient elevations in ALT and AST were observed in 11.25% and 2.40% of patients, respectively, with most normalizing by 3 months.

Conclusions:

  • Intensive atorvastatin therapy (40 mg daily) is a safe and effective treatment strategy for patients with acute myocardial infarction.
  • The regimen leads to significant improvements in lipid profiles and inflammatory markers, contributing to patient recovery.
  • Monitoring for liver enzyme elevations is recommended, as transient increases are manageable.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...